secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0000950170-23-026351
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Director Beth Seidenberg resigns; shareholders reject officer exculpation amendment at annual meeting
--------------------------------------------------------------------------------

- Director Beth Seidenberg resigned from Board effective June 1, 2023, to pursue other activities.
- Board reduced from eight to seven directors.
- At annual meeting, stockholders elected Pascal Touchon, Carol Gallagher, and Maria Grazia Roncarolo as directors.
- Advisory vote on executive compensation approved (71.8M for, 2.2M against).
- Proposal to amend Certificate of Incorporation to exculpate officers was not approved (38.6M for, 35.4M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023026351/0000950170-23-026351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023026351/atra-20230531.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-026351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer